Enhanced Potential of Myricx’s NMT Inhibitor Payloads with Dual Senolytic and Cytotoxic Modes of Action as ADC Cancer Therapies
November 27, 2023 11:00 ET
|
Myricx Bio
Data published today in Nature Cell Biology by Myricx collaborators at the MRC-LMS (Laboratory of Medical Sciences) led by Prof. Jesús Gil have uncovered the central role of N-myristoyltransferase...
Myricx Bio Enters into an Exclusive Antibody License Agreement with WuXi Biologics
November 21, 2023 04:00 ET
|
Myricx Bio
LONDON and SHANGHAI, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug...
Myricx Bio Appoints Dr Chris Martin, Biotech Entrepreneur and ADC Pioneer, as Chairman of its Board of Directors
November 15, 2023 03:00 ET
|
Myricx Bio
LONDON, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focused on the discovery and development of a completely novel class of antibody-drug conjugate (ADC) payloads...
Myricx Bio to Present Preclinical Data Validating NMTi as a Novel ADC Payload Class
October 17, 2023 07:00 ET
|
Myricx Bio
Preclinical efficacy studies validate Myricx Bio’s proprietary N-Myristoyltransferase inhibitor (NMTi) payload platformComplete tumour regressions across a range of solid tumour xenograft models for...
Myricx Expands its ADC Expertise with the Appointment of Francesca Zammarchi as CSO
October 04, 2023 04:00 ET
|
Myricx Bio
LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selectively cytotoxic payloads for...
Myricx Expands its Leadership Team with the Appointment of Dr. Robert McLeod as VP Clinical Development
September 13, 2023 04:00 ET
|
Myricx Bio
LONDON, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Myricx Enters into Antibody License Agreement with Biocytogen
September 07, 2023 07:00 ET
|
Myricx Bio
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK biotech company focusing on the discovery and development of a completely novel class of selective cytotoxic payloads for...
Myricx Pharma Presents Positive Pre-clinical PoC Data at AACR for its N-Myristoyltransferase inhibitor (NMTi) ADC Programme Alongside New Biology on Novel MoA for NMTi
April 17, 2023 13:30 ET
|
Myricx Pharma
New antibody drug conjugate (ADC) programme unveiled, with demonstration of positive pre-clinical proof of concept for Myricx N-myristoyltransferase inhibitors (NMTi) as a completely novel ADC payload...